Anavex Life Sciences (CH:12X1)
NASDAQ:12X1
Total Valuation
Anavex Life Sciences has a market cap or net worth of CHF196.61M. The enterprise value is $115.68M.
Market CapCHF196.61M
Enterprise Value$115.68M
Share Statistics
Anavex Life Sciences has ― shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding―
Owned by Insiders1.65%
Owned by Institutions4.06%
Financial Efficiency
Anavex Life Sciences’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -54.19%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.45
Return on Invested Capital (ROIC)-54.19%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee0.00
Profits Per Employee-1.10M
Employee Count42
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Anavex Life Sciences is ―. Anavex Life Sciences’s PEG ratio is -4.29.
PE Ratio―
PS Ratio0.00
PB Ratio8.00
Price to Fair Value8.00
Price to FCF-19.44
Price to Operating Cash Flow-6.85
PEG Ratio-4.29
Income Statement
In the last 12 months, Anavex Life Sciences had revenue of 0.00 and earned -46.38M in profits. Earnings per share was -0.54.
Revenue0.00
Gross Profit0.00
Operating Income-51.41M
Pretax Income-46.38M
Net Income-46.38M
EBITDA-46.38M
Earnings Per Share (EPS)-0.54
Cash Flow
In the last 12 months, operating cash flow was -34.08M and capital expenditures 0.00, giving a free cash flow of -34.08M billion.
Operating Cash Flow-34.08M
Free Cash Flow-34.08M
Free Cash Flow per Share-10.00T>
Dividends & Yields
Anavex Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta―
52-Week Price Change―
50-Day Moving Average―
200-Day Moving Average―
Relative Strength Index (RSI)―
Average Volume (3m)―
Important Dates
Anavex Life Sciences upcoming earnings date is Aug 11, 2026, TBA (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 11, 2026
Ex-Dividend Date―
Financial Position
Anavex Life Sciences as a current ratio of 11.60, with Debt / Equity ratio of 0.00%
Current Ratio11.60
Quick Ratio11.60
Debt to Market Cap0.00
Net Debt to EBITDA2.21
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anavex Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Anavex Life Sciences EV to EBITDA ratio is -14.16, with an EV/FCF ratio of -16.81.
EV to Sales0.00
EV to EBITDA-14.16
EV to Free Cash Flow-16.81
EV to Operating Cash Flow-16.81
Balance Sheet
Anavex Life Sciences has CHF131.75M in cash and marketable securities with CHF0.00 in debt, giving a net cash position of CHF131.75M billion.
Cash & Marketable SecuritiesCHF131.75M
Total DebtCHF0.00
Net CashCHF131.75M
Net Cash Per ShareCHF10.00T>
Tangible Book Value Per ShareCHF1.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Anavex Life Sciences is CHF16.14, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetCHF16.14
Price Target Upside― Downside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast―